Phase 4 N=15 Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study
Depression · Suicidal Ideation
Primary: Percent Change in Contrast of Parameter Estimates (COPE) — 0.29; -2.12; -1.19; -1.33 Percentage change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=376 A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
Overactive Bladder (OAB)
Primary: Participants Tolerability Assessed by the Medication Tolerability Scale of the Overactive Bladder-Satisfaction (OAB-S) Questionnaire at the End of Treatment (EOT)…
Phase 4 N=49 Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder
Depression · Bipolar Disorder
Primary: MADRS Improvement Over 6 Weeks — 10.0; 6.7 units on a scale — p=0.48
Phase 4 N=222 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients
Alzheimer's Disease
Primary: Mean Change From Baseline in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) — -2.0 units on a scale — p=<0.001
Phase 4 N=44 A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
HIV Infections
Primary: Change in the Density of CD3+/CD4+ Cells Per Cubic Millimeter at the Effector Sites in the Duodenal Tissues Following Antiretroviral Therapy Regimen — 24; 89; 119; 566…
Phase 4 N=39 Dutasteride for the Reduction of Alcohol Use in Male Drinkers
Alcoholism · Alcohol Abuse · Alcohol Dependence
Primary: Change Number of Standard Drinks Per Week. — -26.2; -25.5 standard drinks per week — p=0.9
Phase 4 N=32 Guided Bone Regeneration Around Immediate Implants
Missing Tooth
Primary: Change in Thickness of Buccal Bone — .73; .86; .63; .66 millimeters
Phase 4 N=259 Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma
Asthma
Primary: The Percentage of Participants With Asthma Who Rated the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrated Correct Use of the Inhaler at the…
Phase 4 N=6 Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C
Hepatitis C, Chronic · HIV
Primary: Proportion of Subjects With Sustained Virologic Response (SVR12) — 3; 2 Participants
Phase 4 N=278 Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants With COPD Who Rate the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrate Correct Use of the Inhaler at the End of…
Phase 4 N=8 Pharmacokinetics of Voriconazole in Obese Subjects
Healthy
Primary: Steady-State Cmax and Cmin of Two Voriconazole Dosing Regimens — 2.36; 4.16; 0.81; 1.76 mg/L
Phase 4 N=24 Ketamine For Suicidal Ideation
Suicidal Ideation
Primary: Change in Beck Scale for Suicidal Ideation (BSSI) — 10.8; 14.0 units on a scale — p=0.32
Phase 4 N=11 Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)
Pulmonary Infections
Primary: Percent Reduction in Oxygen Requirement From Baseline — 5.4; 16.5 percentage FiO2
Phase 4 N=2,590 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants
Diphtheria · Tetanus · Poliomyelitis
Primary: Number of Subjects Reporting Any Solicited Local and General Symptoms — 855; 907; 706; 929 Subjects
Phase 4 N=24 A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Hepatitis B, Chronic
Primary: Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL) — 7 participants